Compare BHP Billiton Limited (BHP) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BHP Billiton Limited vs Sanofi SA — how do they compare? BHP Billiton Limited trades at $90.86 (market cap $229.15B), while Sanofi SA trades at $43.54 (market cap $104.30B). The key difference: BHP Billiton Limited is far larger — about 2.2× Sanofi SA's market cap, and Sanofi SA pays the higher dividend (5.55%). Which is the better fit depends on your goals.
| BHP | SNY | |
|---|---|---|
Market Cap | $229.15B | $104.30B |
Sector | Basic Materials | Health |
52-Week High | $93.15 | $52.34 |
52-Week Low | $52.14 | $41.33 |
Enterprise Value | $243.35B | $124.19B |
Dividend Yield | 2.95% | 5.55% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BHP trades at $90.61, up 0.22% with a bullish technical signal supported by moving averages. The company reported mixed Q4 2025 earnings, missing EPS estimates but maintaining strong profitability with 18.97% net margins. Recent operational challenges include strikes at Port Hedland iron ore operations, while copper production declines in Chile. Valuation metrics show a P/E of 22.36 and P/B of 4.54, reflecting premium pricing relative to historical levels.
The outlook remains cautiously optimistic with analyst consensus leaning hold (64.52%) amid labor disputes and production volatility. Key opportunities include exposure to AI-driven copper demand growth, while risks center on strike impacts and fluctuating commodity prices. The stock's current technical strength faces fundamental headwinds from operational disruptions.
SNY trades at $43.48, showing minimal daily change. The technical outlook is neutral with mixed signals, while the stock hovers near its pivot point of $44. Fundamentally, the company reported strong Q2 2026 earnings, beating estimates with EPS of $1.21 versus $1.10 expected, and raised its 2026 sales guidance. Revenue for 2025 was $46.72B with a net income margin of 16.72%, though a decline is projected for 2026. Recent news highlights regulatory approvals for new drugs and strategic shifts under a new CEO.
The investment outlook is cautiously optimistic, supported by earnings beats and positive guidance, but tempered by a projected profit margin contraction in 2026 and a neutral analyst consensus. Key opportunities include growth from Dupixent and new drug approvals, while risks involve pipeline setbacks, competitive pressures, and potential legal challenges. The stock presents a value case with a reasonable P/E of 23.27, but requires monitoring of execution under new leadership.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BHP Billiton Limited
BHP Group Limited operates as a mining company. The Company engages in the exploration, development, production, and processing of iron ore, metallurgical coal, and copper. BHP Group serves customers worldwide.
Read more on BHP →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
